Vasoactive Agents for the Management of Variceal Bleeding: A Mixed Treatment Comparison Network Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials

Kannan Sridharan; Gowri Sivaramakrishnan

doi:10.1055/a-0846-3071

Drug Research, Table of Contents

Drug Res (Stuttg) 2019; 69(09): 487-495
DOI: 10.1055/a-0846-3071

Original Article

Vasoactive Agents for the Management of Variceal Bleeding: A Mixed Treatment Comparison Network Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials

Kannan Sridharan

¹Department of Pharmacology and Therapeutics, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain

,

Gowri Sivaramakrishnan

²School of Oral Health, College of Medicine, Nursing and Health Sciences, Fiji National University, Suva, Fiji Islands

› Author Affiliations

Abstract

Background Vasoactives such as terlipressin, somatostatin, vasopressin, octreotide and nitrates are commonly used to treat variceal bleeding. The present study is a network meta-analysis comparing the efficacy and safety of the above vasoactive agents for treating variceal bleeding.

Methods Electronic databases were searched for appropriate randomized clinical trials evaluating vasoactives in cirrhotic patients with variceal bleeding. Random-effects model was used to generate the pooled estimates. Mortality was the primary outcome and bleeding control, re-bleeding rate, hospital stay, blood transfusion requirements and adverse events were the secondary outcome measures.

Results Fifty randomized clinical trials were included of which 37 were included for the primary outcome. The overall analysis did not reveal any significant difference in the mortality risk between any of the vaso-active drugs except for terlipressin that had statistically significant benefits from direct pooled estimates. Somatostatin and terlipressin showed significant reduction in the mortality risks at 24 h. Terlipressin significantly reduced re-bleeding rate; somatostatin and vasopressin were associated with better hemostasis; and terlipressin and vasopressin significantly reduced the requirement for blood transfusion. Terlipressin, vasopressin and glyceryltrinitrate/vasopressin were also associated with increased risk of adverse events.

Conclusion Terlipressin could be the best agent in the vasoconstrictor category for managing variceal bleeding. Somatostatin and vasopressin can serve as alternatives.

Key words

terlipressin - somatostatin - vasopressin - octreotide - nitrates

Full Text

References

References
1 Biecker E. Gastrointestinal bleeding in cirrhotic patients with portal hypertension. ISRN Hepatology 2013; 2013
2 Garcia-Tsao G, Sanyal AJ, Grace ND. et al. Practice guidelines committee of the american association for the study of liver diseases; practice parameters committee of the american college of gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 922-938
3 Abraldes JG, Villanueva C, Bañares R. et al. Spanish cooperative group for portal hypertension and variceal bleeding. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol 2008; 48: 229-236
4 Tripathi D, Stanley AJ, Hayes PC. et al. Clinical Services and Standards Committee of the British Society of Gastroenterology. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2015; 64: 1680-1704
5 The American Society for Gastrointestinal Endoscopy . The role of endoscopy in the management of variceal hemorrhage. Gastrointestinal endoscopy 2014; 2: 221-227
6 Döhler KD, Walker S, Mentz P. et al. Vasoconstrictive therapies for bleeding esophageal varices and their mechanisms of action. Z Gastroenterol 2003; 41: 1001-1016
7 Wells M, Chande N, Adams P. et al. Meta-analysis: Vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther 2012; 35: 1267-1278
8 Hutton B, Salanti G, Caldwell DM. et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med 2015; 162: 777-784
9 Higgins JPT, Green S.(editors) Cochrane handbook for systematic reviews of interventions. 5.1.0 edition Available from www.cochranehandbook. org (last accessed on 1 May 2017
10 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558
11 Van Rhee HJ, Suurmond R, Hak T. User manual for Meta-Essentials: Workbooks for meta-analysis (Version 1.0). Rotterdam, The Netherlands: Erasmus Research Institute of Management; Available from www.erim.eur.nl/research-support/meta-essentials (accessed on 02 Jun 2017
12 Thorlund K, Engstrom J, Wetterslev J et al. Trial sequential analysis. Copenhagen trial unitAvailable at http://www.ctu.dk/tools-and-links/trial-sequential-analysis.aspx (Accessed on 02 June 2017
13 Walker S, Kreichgauer HP, Bode JC. Terlipressin (glypressin) versus somatostatin in the treatment of bleeding esophageal varices--final report of a placebo-controlled, double-blind study. Z Gastroenterol 1996; 34: 692-698
14 Huang CC, Sheen IS, Chu CM. et al. A prospective randomized controlled trial of sandostatin and vasopressin in the management of acute bleeding esophageal varices. Changgeng Yi Xue Za Zhi 1992; 15: 78-83
15 Söderlund C, Magnusson I, Törngren S. et al. Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 1990; 25: 622-630
16 Chon CY, Jeong JI, Paik YH. et al. Comparison of somatostatin and vasopressin in the control of acute esophageal variceal hemorrhage: A prospective randomized trial. Korean J Hepatol 2000; 6: 468-473
17 Saari A, Klvilaakso E, Inberg M. et al. Comparison of somatostatin and vasopressin in bleeding esophageal varices. Am J Gastroenterol 1990; 85: 804-807
18 Hafta A, Yazar A, Pata C. Comparison of terlipressin plus sclerotherapy with somatostatin plus sclerotherapy to control bleeding from esophageal varices in Child C cirrhosis patients. Turk J Gastroenterol 2001; 12: 95-99
19 Seo YS, Park SY, Kim MY. et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology 2014; 60: 954-963
20 Lee HY, Lee HJ, Lee SM. et al. A prospective randomized controlled clinical trial comparing the effects of somatostatin and vasopressin for control of acute variceal bleeding in the patients with liver cirrhosis. The Korean J Internal Medicine 2003; 18: 161-166
21 Zuberi BF, Baloch Q. Comparison of endoscopic variceal sclerotherapy alone and in combination with octreotide in controlling acute variceal hemorrhage and early rebleeding in patients with low-risk cirrhosis. Am J Gastroenterol 2000; 95: 768-771
22 Shah HA, Mumtaz K, Jafri W. et al. Sclerotherapy plus octreotide versus sclerotherapy alone in the management of gastro-oesophageal variceal hemorrhage. J Ayub Med Coll Abbottabad 2005; 17: 10-14
23 Kumar A, Jha SK, Mittal VV. et al. Addition of somatostatin after successful endoscopic variceal ligation does not prevent early rebleeding in comparison to placebo: A double blind randomized controlled trial. J Clin Exp Hepatol 2015; 5: 204-212
24 Chiu KW, Sheen IS, Liaw YF. A controlled study of glypressin versus vasopressin in the control of bleeding from oesophageal varices. J Gastroenterol Hepatol 1990; 5: 549-553
25 Silvain C, Carpentier S, Sautereau D. et al. Terlipressin plus transdermal nitroglycerin vs. octreotide in the control of acute bleeding from esophageal varices: a multicenter randomized trial. Hepatology 1993; 18: 61-65
26 Junquera F, López-Talavera JC, Mearin F. et al. Somatostatin plus isosorbide 5-mononitrate versus somatostatin in the control of acute gastro-oesophageal variceal bleeding: a double blind, randomised, placebo controlled clinical trial. Gut 2000; 46: 127-132
27 Primignani M, Andreoni B, Carpinelli L. et al. Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: a randomized, double-blind, placebo-controlled, multicenter trial. New Italian Endoscopic Club. Hepatology 1995; 21: 1322-1327
28 Sung JJ, Chung SC, Yung MY. et al. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet 1995; 346: 1666-1669
29 Seo YS, Um SH, Hyun JJ. et al. A prospective study comparing the efficacy of early administration of terlipressin and somatostatin for the control of acute variceal bleeding in patients with cirrhosis]. Korean J Hepatol 2006; 12: 373-384
30 Kim SH, Ham JH, Park JW. et al. Comparison of the effects and complications of combined therapies using endoscopic variceal ligation with octreotide or terlipressin in the control of acute esophageal variceal bleeding. Korean J Med 2005; 68: 149-156
31 Lee GH, Cho SW, Kim HJ. et al. Endoscopic variceal ligation plus octreotide versus variceal ligation alone for the prevention of early rebleeding from esophageal varices. Korean J Hepatol 1999; 5: 299-305
32 Hwang SJ, Lin HC, Chang CF. et al. A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding. J Hepatol 1992; 16: 320-325
33 Gøtzsche PC, Gjørup I, Bonnén H. et al. Somatostatin vs placebo in bleeding oesophageal varices: randomised trial and meta-analysis. BMJ 1995; 310: 1495-1498
34 de Franchis R, Arcidiacono PG, Carpinelli L. et al. Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: A multicenter, double-blind study. New Italian Endoscopic Club. Hepatology 1993; 18: 1102-1107
35 Calès P, Masliah C, Bernard B. et al. French Club for the Study of Portal Hypertension. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N Engl J Med 2001; 344: 23-28
36 Levacher S, Letoumelin P, Pateron D. et al. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995; 346: 865-868
37 Feu F, Ruiz del Arbol L, Bañares R. et al. Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal Bleeding Study Group. Gastroenterology 1996; 111: 1291-1299
38 Avgerinos A, Nevens F, Raptis S. et al. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomized trial. Lancet 1997; 350: 1495-1499
39 Cho SB, Park KJ, Lee JS. et al. Comparison of terlipressin and octreotide with variceal ligation for controlling acute esophageal variceal bleeding--a randomized prospective study. Korean J Hepatol 2006; 12: 385-393
40 D'Amico G, Politi F, Morabito A. et al. Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial. Hepatology 1998; 28: 1206-1214
41 Jenkins SA, Baxter JN, Critchley M. et al. Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage. BMJ 1997; 315: 1338-1341
42 Pedretti G, Elia G, Calzetti C. et al. Octreotide versus terlypressin in acute variceal hemorrhage in liver cirrhosis. Emergency control and prevention of early rebleeding. Clin Investig 1994; 72: 653-659
43 Chitapanarux T, Ritdamrongthum P, Leerapun A. et al. Three-day versus five-day somatostatin infusion combination with endoscopic variceal ligation in the prevention of early rebleeding following acute variceal hemorrhage: A randomized controlled trial. Hepatol Res 2015; 45: 1276-1282
44 Bruha R, Marecek Z, Prochazka V. et al. Double-blind randomized multicenter study comparing the efficacy and safety of 10-day to 5-day terlipressin treatment of bleeding esophageal varices. Hepatogastroenterology 2009; 56: 390-394
45 Azam Z, Hamid S, Jafri W. et al. Short course adjuvant terlipressin in acute variceal bleeding: a randomized double blind dummy controlled trial. J Hepatol 2012; 56: 819-824
46 Bruha R, Marecek Z, Spicak J. et al. Double-blind randomized, comparative multicenter study of the effect of terlipressin in the treatment of acute esophageal variceal and/or hypertensive gastropathy bleeding. Hepatogastroenterology 2002; 49: 1161-1166
47 Abid S, Jafri W, Hamid S. et al. Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial. Am J Gastroenterol 2009; 104: 617-623
48 Zhang HB, Wong BC, Zhou XM. et al. Effects of somatostatin, octreotide and pitressin plus nitroglycerine on systemic and portal haemodynamics in the control of acute variceal bleeding. Int J Clin Pract 2002; 56: 447-451
49 Zhou Y, Qiao L, Wu J. et al. Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy: a controlled study. J Gastroenterol Hepatol 2002; 17: 973-979
50 Besson I, Ingrand P, Person B. et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995; 333: 555-560
51 Hu RH, Lee PH. Open, randomized, comparative study of efficacy and safety between Haemopressin and Glypressin in treating acute esophageal varices hemorrhage. Hepatogastroenterology 2008; 55: 448-452
52 Morales GF, Pereira Lima JC, Hornos AP. et al. Octreotide for esophageal variceal bleeding treated with endoscopic sclerotherapy: A randomized, placebo-controlled trial. Hepatogastroenterology 2007; 54: 195-200
53 Shiha GHM, El-Said SS, Farag FM. et al. Octreotide infusion plus emergency sclerotherapy versus sclerotherapy alone for the control of bleeding oesophageal varices: a prospective randomized clinical trial. Mansoura Med J 1996; 26: 109-121
54 Kullavanuaya P, Manotaya S, Thong-Ngam D. et al. Efficacy of octreotide in the control of acute upper gastrointestinal bleeding. J Med Assoc Thai 2001; 84: 1714-1720
55 Valenzuela JE, Schubert T, Fogel MR. et al. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. Hepatology 1989; 10: 958-961
56 Lin HJ, Wang K, Perng CL. et al. Octreotide and heater probe thermocoagulation for arrest of peptic ulcer hemorrhage. A prospective, randomized, controlled trial. J Clin Gastroenterol 1995; 21: 95-98
57 Burroughs AK, McCormick PA, Hughes MD. et al. Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding. Gastroenterology 1990; 99: 1388-1395
58 Freeman JG, Cobden I, Record CO. Placebo-controlled trial of terlipressin (glypressin) in the management of acute variceal bleeding. J Clin Gastroenterol 1989; 11: 58-60
59 Freitas DS, Sofia C, Pontes JM. et al. Octreotide in acute bleeding esophageal varices: a prospective randomized study. Hepatogastroenterology 2000; 47: 1310-1314
60 Clanet J, Tournut R, Fourtanier G. et al. Treatment of bleeding oesophageal varices in cirrhotic patients with pitressin. A controlled study (author’s transl). Acta Gastroenterol Belg 1978; 41: 539-543
61 Rengasamy S, Ali SM, Sistla SC. et al. Comparison of 2 days versus 5 days of octreotide infusion along with endoscopic therapy in preventing early rebleed from esophageal varices: a randomized clinical study. Eur J Gastroenterol Hepatol 2015; 27: 386-392
62 Fourtanier G, Tournut R, Clanet J. et al. Efficacy of vasopressin in the treatment of gastrointestinal hemorrhage caused by the rupture of esophageal varices. Randomized study: preliminary results. Therapie 1977; 32: 283-286
63 Garcia-Tsao G, Abraldes JG, Berzigotti A. et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017; 65: 310-335
64 World Gastroenterology Organization global guidelines. Available at http://www.worldgastroenterology.org/UserFiles/file/guidelines/esophageal-varices-english-2014.pdf (Accessed on 22 Aug 2017)
65 Wechowski J, Connolly M, Woehl A. et al. An economic evaluation of vasoactive agents used in the United Kingdom for acute bleeding oesophageal varices in patients with liver cirrhosis. Curr Med Res Opin 2007; 23: 1481-1491
66 de Franchis R, Baveno VI. Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63: 743-752

Supplementary Material

Supporting Information